Guide — Oncology
Breast Cancer Nursing Care
The most common cancer in women. Nursing care spans screening and early detection, distinguishing a benign from a malignant mass, supporting patients through surgery and adjuvant therapy, and the lifelong priority of lymphedema prevention on the affected side.
9 min read · Oncology
Educational use only. Diagnosis, staging, and treatment selection are provider-directed and individualized. This guide is educational background for nursing care. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Overview
Most breast cancers are adenocarcinomas arising in the ducts (ductal) or lobules (lobular), ranging from non-invasive ductal carcinoma in situ (DCIS) to invasive disease. Tumors are characterized by hormone-receptor status (ER/PR) and HER2 status, which drive treatment. Spread is most often to the axillary lymph nodes first, then to bone, lung, liver, and brain. Inflammatory breast cancer is an aggressive form presenting as a red, warm, edematous (peau d’orange) breast — not an infection.
Key Concepts
Risk factors
Being female and older are the biggest. Others: BRCA1/BRCA2 mutations and family history, early menarche/late menopause and nulliparity (more lifetime estrogen), prior chest radiation, obesity, alcohol, and hormone therapy. Most patients have no identifiable risk beyond age.
Benign vs malignant mass
A malignant lump tends to be hard, fixed, irregular, single, and painless, often upper-outer quadrant, with skin dimpling, nipple retraction/discharge, or peau d’orange. A benign mass (fibroadenoma, cyst) is more often soft/rubbery, mobile, smooth, and sometimes tender. Any new mass needs evaluation (see the comparison chart).
Receptor status & treatment
ER/PR-positive tumors respond to endocrine therapy (tamoxifen pre-menopause; aromatase inhibitors post-menopause). HER2-positive tumors are treated with trastuzumab (monitor cardiac function). Triple-negative (ER/PR/HER2 all negative) relies on chemotherapy and is more aggressive. Surgery, radiation, and chemo are combined based on stage.
Surgery & nodes
Breast-conserving lumpectomy (+ radiation) or mastectomy; a sentinel lymph node biopsy (SLNB) samples the first draining node, and a positive result may lead to fuller axillary dissection (ALND) — which raises lymphedema risk (see the surgery & lymphedema reference).
Assessment Findings
Assess for a painless hard mass, skin or nipple changes (dimpling, retraction, peau d’orange, bloody or unilateral discharge), and palpable axillary nodes. Review screening history and risk factors. After surgery, monitor the incision and drains, the affected arm’s circulation/sensation/range of motion, and pain. Assess the patient’s emotional response — body image, fear, and decision-making support are central.
Nursing Priorities
Protect the affected arm
After axillary surgery, the operative-side arm is at lifelong lymphedema risk: no BP measurements, venipuncture, IVs, or injections in that arm; avoid constrictive clothing/jewelry; elevate the arm; and teach signs of lymphedema and infection. Encourage early, gentle range-of-motion exercises as ordered.
Post-op care
Manage incisional pain, care for surgical drains (empty/record output), position the arm on a pillow, and watch for hematoma or infection. Reinforce when to resume activity and exercises to restore shoulder mobility.
Support adjuvant therapy
Educate about chemotherapy side effects and neutropenia, radiation skin care, and endocrine therapy (tamoxifen’s VTE/endometrial risk; aromatase-inhibitor bone loss) or HER2 therapy (cardiac monitoring). Reinforce adherence over the long course.
Address body image and coping
Provide emotional support, discuss reconstruction options and prostheses, and connect patients to support resources. Involve them in decisions about treatment.
Therapeutic Communication Considerations
A breast cancer diagnosis touches identity, sexuality, and mortality. Use open-ended questions, allow silence, and let the patient lead on how much to discuss. Validate fears about appearance and prognosis without false reassurance, and respect varied coping styles and decisions (lumpectomy vs mastectomy, reconstruction or not). Include partners/family as the patient wishes, and be sensitive to fertility concerns in younger patients before chemotherapy.
Patient & Family Education
Teach breast awareness and screening (regular mammography per guidelines; report any new lump or skin/nipple change promptly). After surgery, teach affected-arm precautions and lymphedema prevention, drain care, and exercises. Explain the purpose and side effects of each therapy and the importance of adherence and follow-up surveillance. Encourage genetic counseling when BRCA or strong family history is present.
NCLEX Pearls
- ✦Malignant mass = hard, fixed, irregular, painless (often upper-outer quadrant) with skin dimpling or nipple retraction.
- ✦After axillary node surgery: NO BP, venipuncture, IVs, or injections in the affected arm — lifelong lymphedema precaution.
- ✦ER/PR-positive → endocrine therapy (tamoxifen / aromatase inhibitors); HER2-positive → trastuzumab (monitor cardiac function).
- ✦Tamoxifen raises VTE and endometrial cancer risk; teach to report leg swelling/pain or abnormal vaginal bleeding.
- ✦Peau d'orange + red, warm breast = inflammatory breast cancer (aggressive), not mastitis.
- ✦Sentinel lymph node biopsy samples the first draining node to guide whether a full axillary dissection is needed.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with Oncology Nursing Society (ONS) · National Comprehensive Cancer Network (NCCN) · American Society of Clinical Oncology (ASCO). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →